Figure 6
From: The lichen secondary metabolite atranorin suppresses lung cancer cell motility and tumorigenesis
Atranorin inhibited invasion and suppressed tumor growth in vitro and in vivo in different lung cancer cell lines. (a,b) Invasion assays in H460, H1650, H1975, and LLC cells treated with 5 μg/mL atranorin, and quantitative analysis of invaded cell numbers in each cell line. (c,d) Soft agar colony-formation assays in A549, H460, H1650, and LLC cells treated with atranorin (5 μg/mL) and quantitative analysis of colony areas in each group. (e) LLC cells were inoculated subcutaneously into C57BL/6 mice (n = 5 per group) at 2 × 106 cells per mouse. On day 12 of treatment, tumor volume at different time points and tumor weight were measured (p < 0.005). (f) Immunohistochemistry of tumor tissue sections using a Ki-67 antibody displayed nuclear Ki-67 immunoreactivity, a marker of cell proliferation. (g,h) Mouse tissue lysates were analyzed for the expression of KAI1, CD44, c-myc, cyclin-D1, and KITENIN by qRT-PCR (g) or for the expression of STAT, cyclin-D1, c-myc, and KAI by Western blot (h). Representative images are shown from three independent experiments (n = 3). Data represent the mean ± S.E.M. *p < 0.05; **p < 0.01; ***p < 0.001 compared with untreated or DMSO-treated cells.
